Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2017, Article ID 7878605, 7 pages
https://doi.org/10.1155/2017/7878605
Research Article

Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis

1Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece
2Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece
3Hematology Laboratory, University Hospital of Ioannina, Ioannina, Greece
4Hematology Department, University Hospital of Ioannina, Ioannina, Greece

Correspondence should be addressed to Alexandros Makis; rg.iou.cc@sikama

Received 25 October 2017; Accepted 15 November 2017; Published 6 December 2017

Academic Editor: Michelle Baccarani

Copyright © 2017 Alexandros Makis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Abadi, O. Y. Dolberg, and M. H. Ellis, “Immune thrombocytopenia: recent progress in pathophysiology and treatment,” Clinical and Applied Thrombosis/Hemostasis, vol. 21, no. 5, pp. 397–404, 2015. View at Publisher · View at Google Scholar
  2. P. F. Fogarty and J. B. Segal, “The epidemiology of immune thrombocytopenic purpura,” Current Opinion in Hematology, vol. 14, no. 5, pp. 515–519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Arnold, “Bleeding complications in immune thrombocytopenia,” International Journal of Hematology, vol. 2015, no. 1, pp. 237–242, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Rodeghiero, R. Stasi, T. Gernsheimer et al., “Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group,” Blood, vol. 113, no. 11, pp. 2386–2393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Provan, R. Stasi, A. C. Newland et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, vol. 115, no. 2, pp. 168–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. B. Burness, G. M. Keating, and K. P. Garnock-Jones, “Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia,” Drugs, vol. 76, no. 8, pp. 869–878, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Liang, L. Zhang, J. Gao, D. Hu, and Y. Ai, “Rituximab for children with immune thrombocytopenia: A systematic review,” PLoS ONE, vol. 7, no. 5, Article ID e36698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Imbach, “Refractory Idiopathic Immune Thrombocytopenic Purpura in Children: Current and Future Treatment Options,” Pediatric Drugs, vol. 5, no. 12, pp. 795–801, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kühne, G. R. Buchanan, S. Zimmerman et al., “A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group,” Journal of Pediatrics, vol. 143, no. 5, pp. 605–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Glanz, E. France, S. Xu, T. Hayes, and S. Hambidge, “A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children,” Pediatrics, vol. 121, no. 3, pp. e506–e512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. L. G. Robb and K. Tiedeman, “Idiopathic thrombocytopenic purpura: Predictors of chronic disease,” Archives of Disease in Childhood, vol. 65, no. 5, pp. 502–506, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Revel-Vilk, J. Yacobovich, S. Frank et al., “Age and duration of bleeding symptoms at diagnosis best predict resolution of childhood immune thrombocytopenia at 3, 6, and 12 months,” Journal of Pediatrics, vol. 163, no. 5, pp. 1335–e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. P. W. Edslev, S. Rosthøj, I. Treutiger, J. Rajantie, B. Zeller, and O. G. Jonsson, “A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic trombocytopenic purpura in children,” British Journal of Haematology, vol. 138, no. 4, pp. 513–516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Bennett, C. Neunert, R. F. Grace et al., “Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the intercontinental cooperative itp study group registry ii participants,” Pediatric Blood & Cancer, 2017. View at Publisher · View at Google Scholar
  15. K. M. J. Heitink-Pollé, J. Nijsten, C. W. B. Boonacker, M. De Haas, and M. C. A. Bruin, “Clinical and laboratory predictors of chronic immune thrombocytopenia in children: A systematic review and meta-analysis,” Blood, vol. 124, no. 22, pp. 3295–3307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Stiakaki, C. Perdikogianni, C. Thomou et al., “Idiopathic thrombocytopenic purpura in childhood: Twenty years of experience in a single center,” Pediatrics International, vol. 54, no. 4, pp. 524–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Imbach, T. Kühne, D. Müller et al., “Childhood ITP: 12 Months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS),” Pediatric Blood & Cancer, vol. 46, no. 3, pp. 351–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Elalfy, S. Farid, and A. A. Maksoud, “Predictors of chronic idiopathic thrombocytopenic purpura,” Pediatric Blood & Cancer, vol. 54, no. 7, pp. 959–962, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. L. Rand and J. F. Wright, “Virus-associated Idiopathic Thrombocytopenic Purpura,” Transfusion Science, vol. 19, no. 3, pp. 253–259, 1998. View at Publisher · View at Google Scholar
  20. A. Shimanovsky, D. Patel, and J. Wasser, “Refractory immune thrombocytopenic purpura and cytomegalovirus infection: A call for a change in the current guidelines,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 8, no. 1, Article ID e2016010, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Zeller, J. Rajantie, I. Hedlund-Treutiger et al., “Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease,” Acta Paediatrica, vol. 94, no. 2, pp. 178–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. J. Lowe and G. R. Buchanan, “Idiopathic thrombocytopenic purpura diagnosed during the second decade of life,” Journal of Pediatrics, vol. 141, no. 2, pp. 253–258, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. A. Zimmerman and R. E. Ware, “Clinical significance of the antinuclear antibody test in selected children with idiopathic thrombocytopenic purpura,” Journal of Pediatric Hematology/Oncology, vol. 19, no. 4, pp. 297–303, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Tamminga, W. Berchtold, M. Bruin, G. R. Buchanan, and T. Kühne, “Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry i of the Intercontinental Cooperative ITP Study Group (ICIS),” British Journal of Haematology, vol. 146, no. 2, pp. 180–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Samuelsson, T. L. Towers, and J. V. Ravetch, “Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor,” Science, vol. 291, no. 5503, pp. 484–486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. A. R. Crow, S. Song, J. Freedman et al., “IVIG-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity,” Blood, vol. 102, no. 2, pp. 558–560, 2003. View at Publisher · View at Google Scholar · View at Scopus